Clinical Trial Update: Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating anlotinib plus a PD-1 inhibitor as second-line therapy for metastatic pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• PD-1 inhibitor

Snippet

Sponsor: Qingdao Central Hospital | Conditions: Overall Survival | Phase 2 | Status: UNKNOWN